IL1B and Hypertension: Figure 2 summarizes major immunological changes known in human hypertension and preclinical models. Studies on the impact of antiinflammatory and immunomodulatory drugs on BP, including an analysis of the impact of SABV, are needed. In a secondary analysis of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) study, IL-1β inhibition did not reduce BP or incident hypertension; however, cardiovascular mortality, stroke, and MI were reduced in the hypertensive patients. This study did not stratify based on sex, and the population was largely (~75%) male (120).